Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Go back to Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting| (NASDAQ: CRDF) | Delayed: 1.25 -0.05 (3.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.30 | 52 Week High | $ | |||
| Open | $1.30 | 52 Week Low | $ | |||
| Day High | $1.33 | P/E | N/A | |||
| Day Low | $1.24 | EPS | $ | |||
| Volume | 711,945 | |||||
